Development of an innovative treatment for disabling chronic cough associated with idiopathic pulmonary fibrosis
NeRRe Therapeutics is developing orvepitant, a neurokinin (NK)-1 receptor antagonist, as a first-in-class, once-daily, innovative treatment for cough hypersensitivity disorders. Having demonstrated efficacy in patients with refractory or unexplained cough, NeRRe will now continue development in chronic cough caused by the rare, end-stage lung disease idiopathic pulmonary fibrosis (IPF). A dominant feature of this severe and progressive respiratory disease in a high proportion of patients is an uncontrolled and persistent cough that is disabling for these terminally ill patients. The cough is often refractory to medical treatment and there are no approved treatments. Idiopathic pulmonary fibrosis has been declared an orphan disease in both Europe and the United States.
CEO: Mary Kerr.